Axcelis Technologies, Inc. (Nasdaq:ACLS) announced that a major foundry has selected the IntegraTM ES plasma dry strip system to support their most advanced, high-volume device manufacturing facilities. The systems have started shipping this month to multiple fabs worldwide. "We're excited to see the growing momentum for the Integra ES as customers see the wide range of technological capabilities and manufacturing benefits the product offers," noted Bill Bintz, executive vice president of marketing and engineering for Axcelis Technologies.

Axcelis Technologies, Inc. designs, manufactures, and services ion implantation, dry strip, and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and the Asia Pacific.

*****************************************

Power3 Medical Products, Inc. (PWRM.OB)

Dementia is a loss of brain function that occurs with certain diseases. Alzheimer's disease (AD), is one form of dementia that gradually gets worse over time. It affects memory, thinking, and behavior. Memory impairment, as well as problems with language, decision-making ability, judgment, and personality, are necessary features for the diagnosis.

There are two types of AD, early onset and late onset.

* In early onset AD, symptoms first appear before age 60. Early onset AD is much less common than late onset. However, it tends to progress rapidly. Early onset disease can run in families. Several genes have been identified.

* Late onset AD, the most common form of the disease, develops in people age 60 and older. Late onset AD may run in some families, but the role of genes is less clear.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease).

Power3 Medical Products, Inc. applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical Products, Inc. has developed a portfolio of products including BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

Power3 Medical Products, Inc uses the NuroPro Blood Test as a diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer's disease, ALS (Lou Gehrig's disease), and Parkinson's disease. Early detection of these diseases would allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.

For more details, please visit the website: http://www.power3medical.com

*****************************************

Astro-Med, Inc. (NASDAQ:ALOT) announced that Albert W. Ondis retired as a director and Chairman of the Board and Chief Executive Officer of Astro-Med, Inc. effective immediately due to illness. Mr. Ondis is a founder of the Company and has been its Chairman and Chief Executive Officer since 1969. The Board of Directors appointed Jacques V. Hopkins as Chairman of the Board of Directors and Everett V. Pizzuti as Chief Executive Officer to succeed Mr. Ondis. Mr. Hopkins, 80, has been a member of the Board of Directors of the Company since 1969 and serves as chairman of the Company's Audit Committee. Mr. Pizzuti, 74, has been President and Chief Operating Officer of the Company since 1971 and a director since 1985.

Astro-Med, Inc. designs, develops, manufactures, distributes, and services various products that acquire, store, analyze, and present data in multiple formats.

*****************************************

Pointer Telocation Ltd. (Nasdaq:PNTR) reported that the supply and installation of advanced solutions to manage a fleet of vehicles in Brazil in a tri-annual agreement for over $2 million. This is the largest transaction that Pointer signed in Brazil since commencing sales in Brazil a year ago. Pointer entered into an agreement with a leading company in Brazil and installed its solutions in a fleet of over 2,000 motor vehicles. The order will result in a significant increase in the number of the Company's subscribers in Brazil.

*****************************************

GT Solar International, Inc. (NASDAQ:SOLR) announced that it has received orders from two new customers in Asia for polysilicon production equipment totaling $81.7 million. The recent orders include GT's hydrochlorination equipment used for the production of TCS as well as other polysilicon production equipment. The orders will be included in GT Solar's backlog for its first quarter of FY12, which ended on July 2, 2011.

******************************************************************

For FREE Daily Stock Alerts & Updates Sign-up At: http://pennytobuck.com/signup

******************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).